Reports Q3 revenue $554,654 vs. $432,122 last year. “We are proud to announce a record setting quarter for Elevai marked by exceptional growth in both revenue and gross profit,” said Jordan Plews, Elevai’s Chief Executive Officer. “In Q3, our revenue grew over 75% over the previous quarter and this growth is a testament to the effectiveness of our sales strategy and our team’s hard work. Looking ahead, we remain committed to investing in the growth and scale of Elevai while maintaining our focus on operational efficiencies. Additionally, with our recent transition to a public company and the completion of our IPO, we are well-positioned to support the ongoing expansion and development of Elevai.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ELAB:
- ELEVAI Labs, Inc. Expands International Distribution into Europe
- Elevai Labs partners with Skin Sana to expand distribution into Europe
- Opening Day: Fenbo Holdings debuts in another slow week for IPOs
- Biotech Alert: Searches spiking for these stocks today
- Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products